Opthea Ltd has released a press release.
Opthea Presentation for EURETINA Congress
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Opthea
- Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
- Opthea European Patent Application to be Granted
- Opthea Provides Timing Update on OPT-302 Clinical Trials
- Opthea Completes Final Patient Visit in Phase 2b wAMD Trial
Later from Opthea
- Opthea Receives A$14.6m R&D Tax Incentive
- Opthea Presentation for Ophthalmology Innovation Summit
- Opthea Equity Raising Presentation
- Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME
- Opthea Completes Patient Dosing in Phase 2a DME Trial
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea